Status:
COMPLETED
Use of Molecular Breast Imaging (MBI) to Detect Additional Disease in Women With Breast Cancer Who Are About to go to Surgery
Lead Sponsor:
Mayo Clinic
Collaborating Sponsors:
Gamma Medica-Ideas
Conditions:
Breast Cancer
Eligibility:
FEMALE
25+ years
Brief Summary
Conventional mammography is not a reliable method for determining the extent of disease in women with breast cancer. Molecular Breast Imaging (MBI) is a new nuclear medicine technique that allows the ...
Detailed Description
The sensitivity of conventional mammography for evaluation of extent of disease, detection of multifocal breast cancers and contralateral breast cancers is poor. Molecular Breast Imaging (MBI) is a ne...
Eligibility Criteria
Inclusion
- Women with biopsy-proven breast cancer (invasive breast cancer or ductal carcinoma in situ)
Exclusion
- Unable to understand and sign the consent form
- Pregnant or lactating
- Physically unable to sit upright and still for 40 minutes
- Currently receiving neoadjuvant chemotherapy or hormonal therapy
- Currently taking tamoxifen, evista (raloxifene), or an aromatase inhibitor
- Previous mastectomy
- Previous excisional biopsy of the index breast cancer
Key Trial Info
Start Date :
October 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 1 2011
Estimated Enrollment :
98 Patients enrolled
Trial Details
Trial ID
NCT00776308
Start Date
October 1 2008
End Date
February 1 2011
Last Update
January 25 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic
Rochester, Minnesota, United States, 55905